PharmaBlock Sciences Nanjing Inc
SZSE:300725

Watchlist Manager
PharmaBlock Sciences Nanjing Inc Logo
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Watchlist
Price: 35.76 CNY 1.02% Market Closed
Market Cap: 7.1B CNY
Have any thoughts about
PharmaBlock Sciences Nanjing Inc?
Write Note

PharmaBlock Sciences Nanjing Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PharmaBlock Sciences Nanjing Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Total Receivables
ÂĄ406.1m
CAGR 3-Years
43%
CAGR 5-Years
40%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Receivables
ÂĄ3.3B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Receivables
ÂĄ1.1B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Receivables
ÂĄ7.5B
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
10%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Receivables
ÂĄ13.2B
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
11%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Receivables
ÂĄ172.9m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PharmaBlock Sciences Nanjing Inc
Glance View

Market Cap
7.1B CNY
Industry
Pharmaceuticals

PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Intrinsic Value
54.21 CNY
Undervaluation 34%
Intrinsic Value
Price

See Also

What is PharmaBlock Sciences Nanjing Inc's Total Receivables?
Total Receivables
406.1m CNY

Based on the financial report for Sep 30, 2024, PharmaBlock Sciences Nanjing Inc's Total Receivables amounts to 406.1m CNY.

What is PharmaBlock Sciences Nanjing Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
40%

Over the last year, the Total Receivables growth was -10%. The average annual Total Receivables growth rates for PharmaBlock Sciences Nanjing Inc have been 43% over the past three years , 40% over the past five years .

Back to Top